Tiny Gems

Monday Feb 13, 2023 - 10:41 am

InvestorNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Completes Acquisition of the Bahia Project

Energy Fuels (NYSE American: UUUU) (TSX: EFR) today announced completion of its acquisition of 17 mineral concessions between the towns of Prado and Caravelas in the state of Bahia, Brazil, totaling 15,089.71 hectares (approximately 37,300 acres or 58.3 square miles). According to the announcement, closing of the “Bahia Project” followed the Brazilian Government’s approval of the transfers to Energy Fuels’ wholly owned Brazilian subsidiary Energy…

Friday Feb 10, 2023 - 1:22 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates Higher Absorption at Lower Dose Levels

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced it had demonstrated superior CBD blood absorption levels from its patented DehydraTECH(TM)-processed CBD compared to those of published comparators. “In their analysis, Lexaria’s researchers compared the average blood plasma levels of DehydraTECH-CBD at various dose levels (after the steady state or the amount of time needed before a consistent dose of drug achieves a stable plasma level had…

Wednesday Feb 08, 2023 - 2:00 pm

InvestorNewsBreaks – Vision Energy Corp. (VENG) Reports on Final Results of Jetty Simulation Study

Vision Energy (OTCQB: VENG), a forward-looking energy company developing carbon-reduced solutions for the commercial, industrial and transportation sector, has concluded a detailed marine simulation study; the study will be used for the proposed design and future operations of jetty and quay wall infrastructure that will serve VENG’s Green Energy Hub in North Sea Port of Vlissingen, the Netherlands. According to the announcement, Evolution Terminals BV, a…

Monday Feb 06, 2023 - 3:38 pm

InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Robot Roadshow to Take the Spotlight in Vegas

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots, today announced that its Robot Roadshow will land at Silverton Hotel & Casino in Las Vegas, Nevada, from 10:00 a.m. to 2:00 p.m. PT on Feb. 7-9, 2023. The engaging experiential event is designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion. The announcement reads, “The…

Friday Feb 03, 2023 - 11:51 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Pleased with Early Results from Global Clinical Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported that 67 patients have enrolled in the potentially pivotal phase 2 globally cited clinical study comparing drug candidate Berubicin’s effectiveness to second-line standard-of-care chemotherapy drug Lomustine. “The company plans to have more than 200 patients participate in the clinical trial on a 2:1 randomization schema between those receiving Berubicin and those receiving Lomustine… Berubicin’s performance in an initial safety…

Thursday Feb 02, 2023 - 1:44 pm

InvestorNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Partners with Loop Global, Menzies Aviation on LAX Pilot Program

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is collaborating with Menzies Aviation and Loop Global Inc. on a pilot program at the Los Angeles International Airport; the program involves Mullen’s Class 1 EV cargo vans. The world’s largest aviation services company, Menzies operates in 250-plus airports in 58 countries, providing ground, air cargo and fuel services to commercial airports and airlines. Menzies…

Thursday Feb 02, 2023 - 1:28 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Elevate Drug Delivery Across Blood-Brain Barrier by ~1,900%

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed its patented DehydraTECH(TM) technology, which is designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. “DehydraTECH increases effectiveness and improves how these ingredients enter the bloodstream. Benefits of DehydraTECH include: improved speed of onset, with effects felt in minutes; increased bioavailability, with more of the drug delivered into the…

Thursday Feb 02, 2023 - 12:07 pm

InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Inks Five New Contracts for More than a Dozen Machines

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and emergency systems, announced that it has entered five new contracts outlining sales for 13 more machines. The momentum the company created last year is carrying into 2023. The new contracts include a Portland private equity real estate investment firm, which signed a contract for a K5 Autonomous Security Robot (“ASR”) to patrol the parking…

Thursday Feb 02, 2023 - 10:41 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 11,491,120, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The patent’s allowed claims protect the use of portfolio drug SPC-15 in a method of treating stress-induced affective disorders including anxiety and post-traumatic stress…

Wednesday Feb 01, 2023 - 10:14 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received key approval to initiate human dosing of CYB004, its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, through a protocol amendment to its ongoing CYB004-E phase 1 trial. The approval came from an independent ethics committee in the Netherlands. The first-ever trial that evaluates deuterated DMT in humans, the study is being…

Tuesday Jan 31, 2023 - 12:00 pm

InvestorNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT), Fr8App Partners with Leading Mexico-Based Trucking Company to Expand Services

Freight Technologies (NASDAQ: FRGT), a technology company whose custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning and offers a real-time portal for B2B cross-border shipping and domestic shipping within the USMCA region, is partnering with a leading transportation company in Mexico: Majoba Logistics. Fr8App is onboarding MAJOBA Logistics with an eye on expanding transportation capacity for its private fleet service. According to…

Tuesday Jan 31, 2023 - 10:23 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Board Authorizes Stock Repurchase Program

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has announced a stock repurchase program. According to the company, its board of directors has approved the program, which will acquire up to $1 million of the company's common stock. The announcement noted that the company could purchase common stock in a variety of ways, including in the open market…

Monday Jan 30, 2023 - 12:15 pm

InvestorNewsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Releases FY 2022 Financial Numbers, Reports Record Revenue

Golden Matrix Group (NASDAQ: GMGI), a developer, licensor and global operator of online gaming and eCommerce platforms, systems, and gaming content, has released a financial report for FY 2022, the year ended Oct. 31, 2022. Highlights of the report included full-year revenues of $36 million, a 219% increase from the previous year and a revenue record for the company. The report also showed Adjusted EBITDA of…

Monday Jan 30, 2023 - 10:07 am

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Issues 2023 Forecasted Revenue Anticipating >100% YOY Growth

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced revenue guidance of US$90 million to US$105 million for fiscal year 2023. Flora’s 2023 revenue guidance reflects expected organic growth in its House of Brands division and expansion of its Commercial & Wholesale division capabilities. In addition, the forecasted growth incorporates Flora’s new German-based business as established…

Thursday Jan 26, 2023 - 1:27 pm

InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Continues Momentum with Five New Contracts

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and emergency systems, today announced that it has secured five customer expansion orders adding to its ongoing sales growth. The company’s K1 Emergency Communication Systems continue to be big sellers across multiple industries. The new contracts cover K1 upgrades and other products at a New York college, a private university in California, a New Jersey…

Thursday Jan 26, 2023 - 11:30 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The Cybin leadership team is slated to host the event, which will include an update on the company’s development pipeline of differentiated psychedelic-based therapeutics, including CYB003, which is being evaluated for…

Thursday Jan 26, 2023 - 11:10 am

InvestorNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Reports on Special Shareholder Meeting, Announces Key New Hires

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is releasing results from its reconvened Special Meeting of Stockholders. The meeting, which was held on Jan. 25, 2023, included several proxy proposals on the agenda; MULN is reporting that all proposals were approved. According to the announcement, the company has no current plans to effect a reverse split. In addition, the company has until March…

Thursday Jan 26, 2023 - 10:41 am

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Year-End Webcast Review

Flora Growth (NASDAQ: FLGC), a leading outdoor grower, manufacturer and distributor of cannabis products and brands worldwide, has scheduled a webcast to provide an overview of the company’s operational milestones achieved in 2022. The year-end review is slated for Jan. 30, 2023, and will begin at 4:30 p.m. ET. The webinar, which will be prerecorded, will feature Flora Growth chair and CEO Luis Merchan, who…

Tuesday Jan 24, 2023 - 11:58 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The potentially pivotal trial will evaluate Berubicin for the treatment of glioblastoma multiforme (“GBM”), an aggressive brain tumor with an average overall survival…

Tuesday Jan 24, 2023 - 11:07 am

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Working Toward Global Leadership in CBD Space

Flora (NASDAQ: FLGC) has transitioned from the development stage to a full-scale international distributor with operations in over 12 countries worldwide, achieved under Luis Merchan’s tenure as CEO. “Merchan has also spearheaded several mergers and acquisitions, most notably JustCBD and Vessel Brand, which have since set the company up for rapid growth. Flora also secured $34.5 million in financing and signed deals with key retail…

Monday Jan 23, 2023 - 12:24 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pharmaceutical Expert as New Strategic Advisor

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has a new strategic advisor. The company announced that Julian Gangolli, the former president of GW Pharmaceuticals USA, has joined Lexaria as a strategic advisor. During his time at GW Pharmaceuticals, Gangolli managed US Food and Drug Administration approval of Epidiolex(R), the only pure cannabidiol (“CBD”) drug ever approved by the agency; he also oversaw…

Monday Jan 23, 2023 - 11:42 am

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) to Present at Emerging Growth Conference

QSAM Biosciences (OTCQB: QSAM) is developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced that it has been invited to present at the Emerging Growth Conference at 10:15 a.m. ET on Wednesday, Jan. 25, 2023. Leading QSAM’s presentation will be the company’s CEO Douglas Baum and other executive officers, who may subsequently…

Monday Jan 23, 2023 - 10:15 am

InvestorNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Unveils Streamlined, Automated Carrier Onboarding Process

Freight Technologies (NASDAQ: FRGT), a technology company whose custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning, offers a real-time portal for B2B cross-border shipping and domestic shipping within the USMCA region, has announced a new, automated and effortless carrier onboarding process. The new process, states the company, makes it even easier qualified carriers to sign up and move loads with Fr8App. The…

Friday Jan 20, 2023 - 12:26 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic technology drug candidate, toward clinical trials… Short for Apoptotic DNA…

Friday Jan 20, 2023 - 10:29 am

InvestorNewsBreaks — Cepton Inc. (NASDAQ: CPTN) Completed $100M Koito Manufacturing Investment

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, has closed its previously announced $100 million investment with Koito Manufacturing Co. Ltd.; Koito is a long-term automotive Tier 1 partner and current CPTN shareholder. The transaction closed on Jan. 19, 2023, and was in the form of convertible preferred stock. Cepton’s stockholders approved the move at a special meeting held on Jan.…

Thursday Jan 19, 2023 - 9:52 am

InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Secures Contract Renewals for Multiple Key Clients

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and emergency systems, announced that seven key clients have renewed their contracts for another year. The renewal agreements include a hospital, hotel, bank, commercial property developer, mass media company, and two residential communities, representing clients from a variety of industries. Knightscope’s innovative solutions have enabled these clients to reduce crime rates and improve security operations…

Wednesday Jan 18, 2023 - 12:25 pm

InvestorNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Collaborates to Further Unlock Potential of Its Lidar Technology Across Robotics Applications

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, recently announced that it would be further broadening its technological reach by collaborating with Exwayz to develop novel lidar-based perception solutions for mobile robotics applications. “Exwayz is a developer of plug-and-play perception software designed to enable lidar-based 3D mapping, localization, and re-localization as well as object detection and classification… The venture’s lidar-based…

Wednesday Jan 18, 2023 - 10:06 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel (“Kernel”). The study was designed to evaluate Kernel’s Flow(R) wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The results from the feasibility study are very promising and provide further insights…

Tuesday Jan 17, 2023 - 9:56 am

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Provides Strategic Update in Annual Shareholder Letter

Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka has released an annual letter to shareholders. The detailed letter talks about company highlights throughout the year, including the fact that, despite challenges such as global supply chain disruptions and threatening inflation, “Lexaria continues to navigate well and is focused on those things it can control such as applied R&D designed to entice others to work with us…

Thursday Jan 12, 2023 - 2:30 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patented DehydraTECH(TM) drug delivery technology. “For Lexaria, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought Lexaria closer to realizing this…

Thursday Jan 12, 2023 - 12:39 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated phase 1b /2 trial evaluating the company’s novel anthracycline, Berubicin. The study, titled “Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas,” will be conducted at the Pomeranian…

Thursday Jan 12, 2023 - 12:32 pm

InvestorNewsBreaks – Vision Energy Corp. (VENG) Issues Update on Recent Market Activity

Vision Energy (OTC: VENG) (the “Company”) today issued statements regarding recent removal from the OTCQB Market. On Dec. 6, 2022, Vision Energy was informed by the OTC Markets Group Inc. of certain promotional material that encouraged investors to purchase or trade the Company’s common stock. On Jan. 10, 2022, the Company was informed that, due to the ongoing promotional campaign, it would be moved from…

Thursday Jan 12, 2023 - 11:15 am

InvestorNewsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Moves to Acquire MeridianBet Group

Golden Matrix Group (NASDAQ: GMGI) is a developer, licensor and global operator of online gaming and eCommerce platforms, systems and gaming content. The company today announced its entry into a definitive acquisition agreement pursuant to which it has agreed to acquire MeridianBet Group and its related companies in a cash and stock transaction valued at approximately $300 million. MeridianBet is Southeast Europe’s leading business-to-consumer (“B2C”)…

Thursday Jan 12, 2023 - 9:49 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for CYB004 — its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule. “Based on preclinical data, CYB004 has shown promise in treating anxiety disorders. About half of people…

Thursday Jan 12, 2023 - 9:26 am

InvestorNewsBreaks — Cepton Inc. (NASDAQ: CPTN) Announces Approval of Preferred Stock Issue by Shareholders

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, reported that its stockholders approved the company’s proposal to issue 100,000 shares of Series A Convertible Preferred Stock to Koito Manufacturing Co. Ltd. The issuance, which would be for $100 million, is based on the terms of an investment agreement between the two companies that was signed on Oct. 27, 2022. According to…

Wednesday Jan 11, 2023 - 12:04 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine

Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune initiated the GMP manufacturing of drug candidate ADI(TM)-100 for purposes of initiating…

Tuesday Jan 10, 2023 - 12:13 pm

InvestorNewsBreaks – Vision Energy Corp. (VENG) Incorporates Dutch Subsidiaries

Vision Energy (OTCQB: VENG), a forward-looking energy company developing carbon reduced solutions for the commercial, industrial and transportation sector, has incorporated new Dutch subsidiaries. These incorporations are designed to accommodate strategic initiatives for prospective partners, operators and launching customers for VENG’s integrated Green Energy Hub development in North Sea Port of Vlissingen, the Netherlands. According to the announcement, Vision Energy incorporated Vision Hydrogen BV as a…

Tuesday Jan 10, 2023 - 11:02 am

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Releases Shareholder Letter Outlining 2022 Updates, 2023 Milestone Goals

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has provided key updates and milestone goals in a shareholder letter; the letter is from QSAM Biosciences executive chair and cofounder C. Richard Piazza and CEO and cofounder Douglas Baum. The letter noted that QSAM is developing its lead therapeutic radiopharmaceutical drug candidate,…

Tuesday Jan 10, 2023 - 10:20 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in…

Monday Jan 09, 2023 - 2:05 pm

InvestorNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Kicks Off New Year with Multiple New Contracts, Announces Planned Path to Profitability

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, announced that it has secured four new contracts in a successful start of 2023. Under the contracts, Knightscope will deploy three K5 Autonomous Security Robots (“ASRs”) and five K1 Blue Light Towers. The deployment locations include an existing Knightscope channel partner’s regional corporate office in Jacksonville, Florida, an Illinois-based…

InvestorNewsBreaks

NewsBreak Category: Tiny Gems

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions